Press Releases

Date Title  
Toggle Summary Aimmune to Present at the JMP Securities Life Sciences Conference
BRISBANE, Calif. --(BUSINESS WIRE)--Jun. 12, 2019-- Aimmune Therapeutics, Inc.  (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas , M.D., will present at the JMP
Toggle Summary Aimmune Therapeutics Discusses AR101’s Cost-Effectiveness and Demonstrated Clinical Benefits at ICER Meeting
Company to Share Updated Clinical Data on AR101 and Provide Perspective on Its Value to Society BRISBANE, Calif. --(BUSINESS WIRE)--Jun. 11, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, will present at the
Toggle Summary Aimmune to Participate in the Goldman Sachs 40th Annual Healthcare Conference
BRISBANE, Calif. --(BUSINESS WIRE)--Jun. 5, 2019-- Aimmune Therapeutics, Inc.  (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of its Executive Management Team will participate in a fireside chat at the Goldman
Toggle Summary Data from Two Studies Confirm Quality of Life and Psychosocial Burden of Living with Peanut Allergy
--APPEAL 2: Struggle to Avoid Accidental Peanut Exposure Negatively Impacts Quality of Life for Patients and Families-- --Phase 3 PALISADE Follow-on Study Analysis: Improvements in Quality of Life for Peanut-Allergic Patients after Continued AR101 Treatment-- LISBON, Portugal --(BUSINESS
Toggle Summary New Data from Phase 3 PALISADE Follow-on Study of AR101 for Peanut Allergy Show Continued Immunomodulation Through Daily Dosing Beyond One Year
--Patients tolerated as much as 2,000 mg of peanut protein with fewer adverse events -- --Favorable ongoing and notable immunological changes observed over time-- LISBON, Portugal --(BUSINESS WIRE)--Jun. 4, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing
Toggle Summary Pivotal Phase 3 ARTEMIS Trial Data Demonstrates Consistent Safety and Efficacy of AR101 in Children and Adolescents with Peanut Allergy
LISBON, Portugal --(BUSINESS WIRE)--Jun. 2, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today presented topline results from the pivotal European Phase 3 ARTEMIS clinical trial, which it previously
Toggle Summary Aimmune to Present AR101 Data at European Academy of Allergy and Clinical Immunology 2019 Congress
– Full Results from Phase 3 ARTEMIS Study Will Be Featured – BRISBANE, Calif. --(BUSINESS WIRE)--May 24, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will present AR101 and patient
Toggle Summary New Study Shows More Than Half of Teens with Peanut Allergy Visited the E.R., More Than One-Third Required Hospitalization Due to Accidental Exposure to Peanut
-- 4 in 10 Teens believe they have a great or very great chance or certainty of dying from accidental exposure -- NEW ORLEANS --(BUSINESS WIRE)--May 21, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today
Toggle Summary Aimmune to Present at RBC Capital Markets Global Healthcare Conference
BRISBANE, Calif. --(BUSINESS WIRE)--May 16, 2019-- Aimmune Therapeutics, Inc.  (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its Chief Financial Officer, Eric Bjerkholt , will present at the RBC Capital Markets Global
Toggle Summary Aimmune Announces U.S. FDA Advisory Committee Meeting Date for AR101 for Peanut Allergy
- Company Enters into Commercial Supply Agreement for AR101 - BRISBANE, Calif. --(BUSINESS WIRE)--May 16, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it has been informed by the U.S.